PHARMACEUTICAL giant Pfizer has again demonstrated its dominance in the highly competitive world of drug research, manufacturing and marketing by forecasting strong profits for 2018, according to a CNBC report.
The major gains in revenue arrived largely courtesy of recent reforms to the US tax code which will see more than US$11b injected into the business as a result.
Pfizer also made good financial ground on the back of demand for its pneumonia vaccine Prevnar and rheumatoid arthritis drug Xeljanz.
Prevnar pulled in more than $1.53 billion in sales in the last quarter, up 8.3% on the corresponding period the year before, while Xeljanz jumped by 47.5% to $410m.
Pfizer reported adjusted earnings per share of 62 cents.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 18
